Maiorino MI, et al. - Researchers evaluated the metabolic impacts of combination therapy with insulin and GLP-1RA (combo) vs other injectable therapy. They incorporated 36 randomized controlled trials with 14,636 subjects in the present study. According to results, a significant improvement in glycemic control, weight loss, and similar hypoglycemic risk is seen with insulin and GLP-1RA combination therapy vs other injectable therapies, like placebo/insulin up-titration/GLP-1RA alone or multiple insulin injections (basal plus or basal bolus). The combo produced glycemic control comparable to intensified insulin regimens (basal-plus/basal-bolus) with a reduced risk of hypoglycemia and more weight loss. They concluded that GLP-1RA and insulin in combination could be useful for improving glycemic control in type 2 diabetes.